Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:Q9UIJ5 (Rec)
 58,342 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Histochemical properties, muscle fiber cross-sectional area, muscle fiber length, and the oxidative capacity of masticatory muscles of female rhesus monkeys were assessed following alteration in functional length by an intraoral appliance or by detachment of the muscle. Experimental groups received the appliance only (A); the appliance and subsequent detachment of the masseter (AD); the appliance and detached masseter, but with surgical reattachment of the masseter to the pterygomasseteric sling (ADR); no appliance, but detachment and reattachment of masseter (DR); or an appliance which was removed after 24 weeks to study posttreatment responses (PT). Animals were sacrificed and the muscles were studied at intervals from 4 to 48 weeks after initiation of the experimental period. The results of these studies led to the following conclusions: (1) Stretching the masseter and temporalis muscles within physiological limits did not significantly alter the proportion of fiber types, although oxidative capacity of the fibers was reduced. (2) Fibers with "intermediate" myofibrillar ATPase activity were no more prevalent in experimental than control muscles. (3) The cross-sectional area of Type I fibers of masseter muscles decreased following some experimental procedures, indicating that recruitment of these fibers is the most sensitive to altered jaw function. (4) Minimal alteration of muscle capillarity was induced by any of the experimental procedures. (5) The lengths of masseter muscle fibers in Group PT and of temporalis muscle fibers in groups AD and ADR were greater than in control animals.
Anat Rec 1981 Jun
PMID:Adaptation of the masseter and temporalis muscles following alteration in length, with or without surgical detachment. 645 41

The proerectile properties of three novel alpha(1)-adrenoceptor (alpha(1)-ADR) antagonists with different profiles of selectivity for the alpha(1)-ADR subtypes have been evaluated in anesthetized rats and dogs on intracavernous (IC) injection, in comparison with prazosin and phentolamine. In rats, the tested compounds decreased blood pressure (BP) and increased IC pressure (ICP), as well as the ratio ICP/BP. Rec 15/2841 (alpha(1a)- plus alpha(1L)-ADR-selective antagonist) and Rec 15/2615 (alpha(1b)-ADR selective) were the most potent compounds. The ICP/BP ratios calculated after injection of Rec 15/3039 (alpha(1d)-ADR selective) were not markedly different from those observed after vehicle injection. Prazosin and phentolamine proved poorly active, their main effect being hypotension. Approximate ED(25) values (dose of compound in micrograms inducing 25% increase of ICP/BP ratio) were Rec 15/2615 (22 microgram/kg)>= Rec 15/2841 (29 microgram/kg) > prazosin (136 microgram/kg) > phentolamine (1298 microgram/kg) > Rec 15/3039 (9600 microgram/kg). Submaximal stimulation of the cavernous nerve elicited an ICP rise whose amplitude was not altered by Rec compounds. In contrast, prazosin and phentolamine decreased this ICP rise. All compounds but 15/3039 induced significant increase of the ICP/BP ratio in dogs. Rec 15/2615 proved to be the most interesting compound, inducing significant increases of ICP/BP at doses practically devoid of effects on BP. The rank order of potency in dog in increasing the ICP/BP ratio was similar to that observed in rats. Only at the highest doses tested, all compounds, except Rec 15/3039, decreased the ICP rise elicited by submaximal stimulation of the cavernous nerve. Our data demonstrate that the alpha(1b)- and alpha(1L)-ADR subtypes are functionally relevant for the erectile function in these models, and that alpha(1b)- and/or alpha(1L)-ADR subtypes selective antagonists could represent a real advantage in erectile dysfunction therapy.
 ...
PMID:Effects of intracavernous administration of selective antagonists of alpha(1)-adrenoceptor subtypes on erection in anesthetized rats and dogs. 1068 12